Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...
Business Wire1d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
pharmaphorum3h
Gilead, MSD say HIV combo could be weekly, oral HIV drug
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Le Lézard16h
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Novavax, Inc. and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. ("Novavax" or "the Company") . Investors who purchased Novavax securities are encouraged ...
Le Lézard11h
Chang Gung Memorial Hospital Unveils Cellular Therapy: A Beacon of Hope for Cancer Treatment
Cellular therapy, a revolutionary approach where cells are manipulated outside the body and then reintroduced to treat or prevent diseases, has been recognized in recent years as a highly promising ...
pharmaphorum6d
Gilead and MSD say weekly oral therapy controls HIV
One patient on islatravir/lenacapavir did show a detectable viral load of more than 50 copies/mL at 24 weeks, but fell below that threshold at 30 weeks, according to Gilead and MSD, and two ...
Reuters12h
United States
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...
FiercePharma4d
With Gilead coming fast, GSK bolsters case for long-acting HIV PrEP drug Apretude
But will doctors use it? In its push to gain approval for its long-acting answer lenacapavir, Gilead also has reported stellar results from two phase 3 trials including the PURPOSE 1 study ...
dw4d
HIV treatment breakthroughs: Namibia's success story
But in terms of HIV preventions, there is already another groundbreaking drug called lenacapavir. The anti-HIV compound is already in use, but getting the drug to those who need it most could ...
AllAfrica.com5d
Africa: 'Antiretrovirals Alone Will Not End the HIV Pandemic' - 4 Key Takeaways from #HIVR4P2024
The twice-yearly injectable lenacapavir from Gilead Sciences emerged as a significant innovation, showing promising results in preventing HIV acquisition. Lenacapavir’s potential to be a “game ...
AllAfrica.com6d
Africa: Long-Lasting Protection - The Future of HIV Prevention in Africa
Additionally, lenacapavir, a first-in-class antiretroviral, offers six months of protection and is undergoing regulatory processes. Lenacapavir is indicated for adults with multidrug-resistant HIV ...